3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
604
Carboplatin
374
Paclitaxel
283
Cisplatin
270
Gemcitabine
252
Pemetrexed
194
Bevacizumab
191
Docetaxel
186
Nivolumab
180
Injections
169
Cyclophosphamide
150
atezolizumab
139
Fluorouracil
134
Capecitabine
133
Oxaliplatin
132
Dexamethasone
128
durvalumab
113
Fulvestrant
113
130-nm albumin-bound paclitaxel
110
fludarabine
103
Cetuximab
100
Leucovorin
97
Rituximab
95
venetoclax
90
Lenalidomide
83
enzalutamide
77
Prednisone
77
Azacitidine
74
Irinotecan
73
Doxorubicin
72
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
gadodiamide
×
1 year
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled